Crevicular fluid biomarkers and periodontal disease progression.
Crevicular fluid biomarkers and periodontal disease progression.
复制标题
DOI：
10.1111/jcpe.12194
复制
发表时间：
2014-02
影响因子：
6.7
通讯作者：
Giannobile WV
中科院分区：
文献类型：
--
作者：
Kinney JS;Morelli T;Oh M;Braun TM;Ramseier CA;Sugai JV;Giannobile WV
评估一组龈沟液（GCF）生物标志物作为牙周病进展（PDP）预测因子的能力。100人参加了为期12个月的纵向调查，并根据他们的牙周状况分为4组。每两个月收集一次GCF、临床参数和唾液。每半年采集龈下菌斑和血清。6个月，没有提供牙周治疗。在6个月时，患者接受牙周治疗，并继续参与6-12个月。采用ELISA法检测GCF中MMP-8、MMP-9、OPG、CRP和IL-1β。使用Wilcoxon秩和检验比较稳定和进展参与者之间GCF生物标志物的中位水平差异（p=0.05）。聚类算法用于评估口腔生物标志物将患者分类为稳定或进展的能力。83人完成了为期6个月的监测阶段。除GCF C反应蛋白外，PDP组的所有生物标志物均显著高于稳定患者。聚类分析显示，当生物膜病原体和GCF生物标志物与临床测量相结合时，敏感性水平最高，为74%（95%CI = 61.86）。GCF液体衍生生物标志物的签名与病原体和临床指标相结合，为PDP的区分提供了一种灵敏的指标（ClinicalTrials.gov NCT 00277745）。
Assess the ability of a panel of gingival crevicular fluid (GCF) biomarkers as predictors of periodontal disease progression (PDP). 100 individuals participated in a 12-month longitudinal investigation and categorized into 4 groups according to their periodontal status. GCF, clinical parameters, and saliva were collected bi-monthly. Sub-gingival plaque and serum were collected bi-annually. For 6 months, no periodontal treatment was provided. At 6-months, patients received periodontal therapy and continued participation from 6-12 months. GCF samples were analyzed by ELISA for MMP-8, MMP-9, OPG, CRP and IL-1β. Differences in median levels of GCF biomarkers were compared between stable and progressing participants using Wilcoxon Rank Sum test (p=0.05). Clustering algorithm was used to evaluate the ability of oral biomarkers to classify patients as either stable or progressing. Eighty-three individuals completed the 6-month monitoring phase. With the exception of GCF C-reactive protein, all biomarkers were significantly higher in the PDP group compared to stable patients. Clustering analysis showed highest sensitivity levels when biofilm pathogens and GCF biomarkers were combined with clinical measures, 74% (95% CI = 61,86). Signature of GCF fluid-derived biomarkers combined with pathogens and clinical measures provides a sensitive measure for discrimination of PDP (ClinicalTrials.gov NCT00277745).
登录
查看更多内容
影响因子：
3.7
作者：
Shelburne CE;Shelburne PS;Dhople VM;Sweier DG;Giannobile WV;Kinney JS;Coulter WA;Mullally BH;Lopatin DE
通讯作者：
Lopatin DE
影响因子：
6.7
作者：
Sexton WM;Lin Y;Kryscio RJ;Dawson DR 3rd;Ebersole JL;Miller CS
通讯作者：
Miller CS
影响因子：
4.3
作者：
Becerik, Sema;Ozturk, Veil Ozgen;Emingil, Gulnur
通讯作者：
Emingil, Gulnur
影响因子：
6.7
作者：
MCCULLOCH, CAG
通讯作者：
MCCULLOCH, CAG
影响因子：
3.5
作者：
Mullally, BH;Dace, B;Coulter, WA
通讯作者：
Coulter, WA